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Objectives The authors sought to develop a low-energy electrotherapy that terminates ventricular tachycardia (VT) when
antitachycardia pacing (ATP) fails.
Background High-energy implantable cardioverter-defibrillator (ICD) shocks are associated with device failure, significant mor-
bidity, and increased mortality. A low-energy alternative to ICD shocks is desirable.
Methods Myocardial infarction was created in 25 dogs. Sustained, monomorphic VT was induced by programmed stimula-
tion. Defibrillation electrodes were placed in the right ventricular apex, and coronary sinus and left ventricular
epicardium. If ATP failed to terminate sustained VT, the defibrillation thresholds (DFTs) of standard versus exper-
imental electrotherapies were measured.
Results Sustained VT ranged from 276 to 438 beats/min (mean 339 beats/min). The right ventricular–coronary sinus
shock vector had lower impedance than the right ventricular–left ventricular patch (54.4  18.1  versus 109.8 
16.9 ; p  0.001). A single shock required between 0.3  0.2 J to 5.9  2.5 J (mean 2.64  3.22 J; p 
0.008) to terminate VT, and varied depending upon the phase of the VT cycle in which it was delivered. By con-
trast, multiple shocks delivered within 1 VT cycle length were not phase dependent and achieved lower DFT
compared with a single shock (0.13  0.09 J for 3 shocks, 0.08  0.04 J for 5 shocks, and 0.09  0.07 J for 7
shocks; p  0.001). Finally, a multistage electrotherapy (MSE) achieved significantly lower DFT compared with a
single biphasic shock (0.03  0.05 J versus 2.37  1.20 J; respectively, p  0.001). At a peak shock amplitude
of 20 V, MSE achieved 91.3% of terminations versus 10.5% for a biphasic shock (p  0.001).
Conclusions MSE achieved a major reduction in DFT compared with a single biphasic shock for ATP-refractory monomorphic
VT, and represents a novel electrotherapy to reduce high-energy ICD shocks. (J Am Coll Cardiol 2012;60:
2393–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1001Randomized, prospective clinical trials have demonstrated
that implantable cardioverter-defibrillators (ICDs) decrease
mortality in patients with coronary artery disease or prior
myocardial infarction (MI) who are at increased risk of
ventricular tachycardia (VT) or ventricular fibrillation (1,2).
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accepted August 6, 2012.More than 80% of victims of sudden cardiac death have
coronary artery disease (3), with the most common arrhyth-
mia being sustained monomorphic VT (4). A high-energy
biphasic shock is the only existing electrotherapy when
antitachycardia pacing (ATP) fails to terminate VT. How-
ever, ICD shocks have been shown to damage the myocar-
dium and reduce the quality of life (5,6). Moreover, patients
See page 2399
receiving high-energy shocks have a 2- to 3-fold increase in
mortality (7,8) compared with those who do not receive
shocks. Although it is unclear whether it is the shocks
themselves or a change in underlying cardiac status that
actually causes higher mortality, even inappropriate shocks
(9) are associated with a higher mortality, for example,
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mortality in patients with poor
left ventricular (LV) function.
Despite these disadvantages, al-
ternative low-energy electrother-
apies have not been introduced
into ICD technology since the
incorporation of ATP. The pur-
pose of this study was to develop
a novel electrotherapy that termi-
nates VT with lower energy than
a biphasic shock for ATP-
refractory monomorphic VT.
Methods
Surgical procedures. All animal
procedures were performed in
accordance with the Position of
the American Heart Association
on the use of research animals
(updated in 1985) and were ap-
proved by the Animal Studies
Committee at Washington University. MI was created after
anesthetization of mongrel dogs (n  25) of either sex
eighing 20 to 25 kg, by surgical ligation of the left
nterior descending coronary artery for 2 h, as described
reviously (10). Four days after MI, animals were reanes-
hetized, a median sternotomy was performed, and car-
iopulmonary bypass was initiated after the administra-
ion of heparin.
lectrode configuration. In the 24 dogs that survived MI
1 dog died suddenly 1 day after left anterior descending
oronary artery ligation), a 15-cm2 custom epicardial LV
patch (LVP) was placed over the posterolateral LV, and an
8-F standard defibrillation/bipolar pacing lead (6935,
Medtronic, Minneapolis, Minnesota) was implanted in the
right ventricular (RV) apex (Fig. 1). In 5 animals, an
additional 8-F standard defibrillation lead (6937A,
Medtronic) was placed into the coronary sinus (CS) (Fig. 1).
Pacing was delivered from the RV bipole. Shock therapies
were delivered across the RV-LVP or RV-CS vectors; all
shocks were RV anodal. A bipolar button electrode was
sewn to the RV epicardium for ventricular sensing.
Defibrillation protocol. Four days after MI, loading (2
mg/kg) and maintenance (0.05 mg/kg/min) infusions of
flecainide acetate (Sigma-Aldrich, St. Louis, Missouri)
were administered intravenously. VT was induced by
rapid RV pacing protocols (programmed electrical stim-
ulation). Sustained, monomorphic VT was defined as a
fast but organized ventricular rhythm 500 beats/min,
lasting 30 s. Ventricular fibrillation was defined as an
arrhythmia 500 beats/min, and if induced, terminated
using an external defibrillator. The heart was allowed to recover
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tachycardiation of VT.After monomorphic VT was induced, ATP was at-
tempted. ATP consisted of 8 pacing stimuli, each of 2-ms
duration delivered at a rate of 88% of the VT cycle length
(CL), delivered from the RV bipole at an amplitude 4 times
the ventricular pacing capture threshold current. If ATP failed
to terminate VT, defibrillation thresholds (DFTs) of various
electrotherapies (defined later in the text) were measured.
DFT, in volts, was defined as the peak shock amplitude that
terminated VT. DFT, in joules, was calculated by multiplying
the energy of a single shock by the number of shocks applied (for
multiple-shock and multistage electrotherapies).
Experimental and standard electrotherapies were delivered
using a randomized protocol with respect to sequence to avoid
time bias, using a voltage-regulated, step-up protocol. The
amplitude of the peak shock voltage was increased after each
unsuccessful termination, beginning at twice the minimum
voltage required to capture the ventricle with a 10-ms mono-
phasic shock, until VT was terminated. Reinduction of VT was
attempted after a 5-min recovery period, according to the
protocol. Electrotherapies were delivered from computer-
controlled regulated power supplies (BOP 100-4M, Kepco,
Flushing, New York). Impedances were calculated using a current
probe (A622, Tektronix, Beaverton, Oregon).
Electrotherapies tested. The electrotherapies tested are
shown in Figure 2. One (1MP), 3 (3MP), 5 (5MP), or 7
(7MP) monophasic shocks were delivered within 1 VT CL
(Fig. 2A); each individual shock was 10 ms in duration. A
single biphasic shock (1BP, 6-ms and 4-ms duration of the
first and second phases, respectively; 2:1 ratio of the leading
edge voltages of the 2 phases is shown in Fig. 2B).
Multistage electrotherapy (MSE), shown in Figure 2C,
Figure 1 Anatomic Position of Defibrillation Electrodes
Schematic of a canine heart with the locations of the electrodes used for appli-
cation of electrotherapies. Anteroposterior (left) and posteroanterior (right)
views showing locations of the defibrillation leads and shock vectors (black
arrows). Shocks were delivered from the RV defibrillation coil (RV) to the CS
defibrillation coil (CS), or from the RV coil to epicardial LV defibrillation patch
(LVP). CS  coronary sinus; LVP  left ventricular patch; RA  right atrium;
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CL (Stage 1), followed by 6 MP shocks delivered with an
interval of 88% of the VT CL at twice the ventricular shock
capture voltage (Stage 2), followed by ATP (Stage 3);
individual stages were separated by 100-ms delays.
Statistical analysis. The defibrillation protocol random-
ized the sequence of electrotherapies to prevent the
confounding effects of treatments with respect to time.
Recovery periods were observed after each termination to
prevent carryover effects. DFTs for comparisons of elec-
trotherapies tested were analyzed using a linear mixed-
effects model with animal ID as a random effect and
treatment as a fixed effect. Energy and voltage DFT
values were log transformed to stabilize the variance.
Estimates were calculated with the MIXED procedure in
SAS (version 9.3, SAS Institute, Cary, North Carolina).
Paired Student’s t test was used to compare impedances of
he 2 shock vectors tested, and performed in Prism 5.0c
GraphPad Software, La Jolla, California). Results are
eported as mean SD. A p value of0.05 was considered
Figure 2 Defibrillation Wave Forms
and Low-Energy Electrotherapies
Schematic diagrams of the electrotherapies applied. Pulse widths of individual
shocks were 10 ms. (A) One (1MP), 3 (3MP), 5 (5MP), or 7 (7MP) monophasic
shocks delivered within 1 VT cycle length (CL). (B) A single biphasic shock
(1BP) with pulse widths of 6 ms for the first (positive) phase and 4 ms for the
second (negative) phase. (C) Multistage electrotherapy (MSE). Stage 1 con-
sisted of 3 monophasic shocks delivered in 1 VT CL, followed by a 100-ms
delay. Stage 2 consisted of 6 lower-voltage monophasic shocks delivered at a
rate of 88% of the VT CL, followed by a 100-ms delay. Stage 3 consisted of 8
pacing stimuli, each of 2-ms duration delivered from the endocardial RV lead
(tip to ring) at a rate of 88% of the VT CL. BP  biphasic; MP  monophasic;
VT  ventricular tachycardia; other abbreviations as in Figure 1.ignificant.esults
haracteristics of monomorphic VT in canine hearts
ith 4-day-old infarct. One hundred and ninety episodes
f monomorphic, sustained VT (lasting 30 s) were in-
uced in 16 of the 24 dogs (66.7%) that survived MI; in 8
ogs, only ventricular fibrillation or polymorphic VT could
e induced. VT ranged from 276 to 438 beats/min (mean
39 beats/min). ATP successfully terminated VT in 17 of
70 trials, a success rate of 10.0%.
hase dependence of a single shock. The energy required
or a single shock to terminate VT varied significantly
epending upon the phase of the VT cycle in which it was
elivered (DFT phase dependence) in this in vivo model.
he DFT of a single 10-ms monophasic shock varied
ignificantly when delivered at 0%, 20%, 40%, 60%, or 80%
f the VT CL. Shocks were delivered between the RV coil
nd the LVP. Application of a single shock revealed that the
FT dramatically changed based upon the phase of appli-
ation. Phase-dependent DFT for a single shock was seen in
ll dogs tested (n  5). Across all dogs, the mean DFT of
he optimal phase in each animal compared with the mean
FT of the least effective phase was 0.3 0.2 J versus 5.9
.5 J, respectively (p  0.008). Notably, the optimal phase
varied between animals and could not be determined a
priori.
DFTs of single versus multiple shocks. We hypothesized
that multiple low-energy shocks applied evenly within 1 VT
CL would not have phase dependence, thus enabling a
reduction in the DFT compared with a single shock. After
induction of sustained VT, ATP was attempted. If ATP
failed, 1, 3, 5, or 7 MP shocks (1MP, 3MP, 5MP, or 7MP,
respectively) were applied within 1 VT CL (Fig. 3A). A
single (1MP) 1.1-J MP shock failed to terminate VT (upper
tracing), whereas 3MP, 5MP, and 7MP shocks (of 0.24 J,
0.16 J, and 0.2 J, respectively) terminated VT. Mean DFTs
across all dogs tested (n  6) are summarized in Figure 3B.
In all animals tested, multiple shocks significantly lowered
the DFT compared with a single shock and did not exhibit
phase dependence.
Multistage electrotherapy. Previous electrotherapies were
applied from endocardium to epicardium (RV-LVP vector)
(Fig. 1). To move toward the goal of developing a lead
system that is practical in humans yet enables low DFT, we
tested whether shocks applied entirely within the heart
(RV-CS vector) (Fig. 1) would achieve low impedance. The
mean impedance of shocks delivered between the RV-CS
vector was significantly lower than the RV-LVP vector
(54.4  18.1  versus 109.8  16.9 , respectively, p 
0.001). These results showed that low impedance can be
achieved using transvenous electrodes rather than an epi-
cardial patch electrode.
To further reduce the DFT, we expanded multiple shocks
to a MSE (Fig. 2C). Using the RV-CS vector, MSE was
compared to the existing clinical standard, a single biphasic
shock. After induction of sustained monomorphic VT,
s
r
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delivered according to a randomized protocol. Sample
terminations using a single biphasic shock and MSE are
shown in Figure 4A, where the DFT of a single BP shock
was 200 V (4.56 J) compared with 20 V (0.22 J) for MSE.
Pooled results (n  5 dogs) are shown in Figure 4B. The
mean DFT of MSE was significantly lower than that of a
single biphasic shock in terms of total energy (0.03  0.05
J versus 2.37  1.20 J, respectively; p  0.001) and peak
hock voltage (7.2  6.9 V versus 137.7  43.8 V,
espectively; p 0.001). At a peak shock amplitude of 20 V,
MSE achieved 91.3% of terminations versus 10.5% for a
biphasic shock (p  0.001). Importantly, these results
demonstrate that low DFT can be achieved using trans-
venously implanted leads, and does not require an epicardial
electrode.
Discussion
Our study showed that the DFT of a single shock to
terminate post-MI monomorphic VT in vivo was phase
dependent, and that multiple low-energy shocks delivered
Figure 3 DFTs of Single and Multiple
Monophasic Shock Electrotherapies
(A) Surface electrocardiogram tracings during applications of single and multi-
ple monophasic shock electrotherapies. An 80-V (1.1 J) single monophasic
shock (1MP) failed to terminate VT (top panel). In the same animal, 3 mono-
phasic shocks (3MP; second panel), 5 monophasic shocks (5MP; third panel),
and 7 monophasic shocks (7MP; lower panel) delivered within 1 VT cycle ter-
minated VT successfully with 22 V (0.24 J), 14 V (0.16 J), and 13 V (0.2 J),
respectively. (B) Mean DFTs (logarithmic scale) of 1MP, 3MP, 5MP, and 7MP
with respect to peak voltage (left panel) and total energy (right panel) over
n  6 dogs tested is shown. NS  not significant; other abbreviations as in
Figures 1 and 2.within a single VT CL eliminated phase dependence.Expanding upon this concept, MSE dramatically reduced
the DFT compared with a single biphasic shock for ATP-
refractory monomorphic VT. Importantly, we showed that
MSE (and a single biphasic shock) could be delivered
endocardially using commercially available transvenous de-
fibrillation leads placed in the RV and CS.
In this model, the success rate of ATP was 10%. This
contrasts with human trials in which ATP terminated 78%
to 94% of monomorphic VT 200 beats/min (11–13). In
humans, the efficacy of ATP has been shown to be lower
with increasing rate of VT, terminating 84% of VT episodes
ranging from 188 to 214 beats/min, and only 69% of
episodes ranging from 214 to 250 beats/min (14). Other
studies have shown the success rate for fast VT to range
from 47% to 79% (15–18). The average rate of VT in our
model was 339 beats/min, significantly faster than those
reported in human ATP trials, and likely explains why
ATP was relatively unsuccessful in this model. Impor-
tantly, the low-energy MSE described in this report is
not envisioned as an alternative to ATP. Rather, it is
intended to complement ATP and provide an alternative
Figure 4 Sample Terminations and Mean DFTs
of a Single Biphasic Shock Versus MSE
(A) Surface electrocardiogram (ECG) and ventricular electrogram (VEG) of a ter-
mination of monomorphic VT by a single biphasic shock (1BP) with peak lead-
ing edge voltage of 200 V (4.56 J). Arrows indicate the time of electrotherapy
application. (B) Surface ECG and VEG of a termination of monomorphic VT by
MSE with peak voltage of 20 V (0.22 J). (C) Mean DFTs of a single biphasic
shock (Single Biphasic) and MSE (Multi-Stage) are shown with respect to peak
voltage (left panel) and total energy (right panel). SR  sinus rhythm; other
abbreviations as in Figures 2 and 3.
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when ATP fails.
Our study agrees with in vitro studies in post-MI rabbit
hearts showing the phase dependence of single monophasic
and biphasic shocks (19,20). We found a 20-fold energy
difference between single optimally and poorly timed
shocks, similar to those reported in in vitro studies. Notably,
in both the current in vivo canine study and previously
in vitro rabbit studies, and the optimal phase for single-
shock application could not be predicted a priori.
Lowering the DFT by repetitive shocks was first shown
by Gurvich in 1945 (21). More recently, repetitive sub-
threshold (below the ventricular capture threshold) pacing
was shown to terminate VT in guinea pig hearts when
applied to the endocardium (22). Previous studies in in vitro
rabbit heart preparations showed that multiple shocks ex-
tinguished the re-entrant circuit by maintaining an area of
myocardium refractory to activation, into which the re-
entrant wave front collides (19). It is likely that the
mechanism of defibrillation in the canine MI model of VT
is similar.
The current standard ICD electrotherapy for ATP-
refractory monomorphic VT is a high-energy biphasic
shock. A low-energy electrotherapy would be desirable to
replace the shock if it were effective. The mean DFT of the
MSE in this report was nearly 80-fold lower in energy than
that of a biphasic shock. Moreover, at low voltage (20 V),
MSE achieved significantly more terminations than a bi-
phasic shock, making it a suitable low-energy electrotherapy
to reduce the need for full output ICD shocks.
Nearly all ICD shocks are delivered from the RV coil to
an “active can”/superior vena cava coil configuration, deliv-
ering current, not only through the heart itself, but also
through the chest wall musculature and sensory nerves,
thereby dissipating energy over structures outside of the
heart and causing pain. Implanting commercially available
defibrillation leads in the CS (already Food and Drug
Administration approved for defibrillation from the CS and
azygous vein) and RV enables application of a shock vector
that largely confines energy to the heart itself, and was
shown to be effective for delivering MSE. Notably, this
configuration would still allow ICD shocks to be applied via
the traditional RV to superior vena cava/active can vector
should MSE fail.
Though MSE may require design changes prior to incor-
poration into ICDs, such therapies require significantly lower
voltage for defibrillation, which requires much less time for
charging the capacitor than a full-output ICD shock. Reducing
the number of full-output ICD shocks would likely prolong
battery life and may reduce the malfunction rate of high-
voltage components. Effective low-energy electrotherapy may
be significantly less painful to patients, and importantly, reduce
the likelihood of patients receiving a high-energy shock. Also,
if high-energy shocks are themselves partially responsible for
the increased mortality observed in patients who receive them,effective lower-energy electrotherapy may conceivably reduce
mortality.
Conclusions
In the present study, we found that the DFT of a single
monophasic shock to terminate VT in canine hearts with
healing MI is phase dependent. Multiple shocks delivered
within a single VT CL achieved lower DFTs than a single
randomly timed shock without requiring a priori knowledge
of phase dependence. MSE, which incorporated multiple
MP shocks within the first stage, further reduced the DFT.
MSE is a low-voltage, low-energy electrotherapy that
terminates VT with lower DFT than a single biphasic
shock, yet it is significantly more effective than ATP in this
model. If successful in humans, MSE may reduce the need
for high-energy shocks.
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